{"pmid":32455478,"title":"A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an issue.","text":["A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an issue.","We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID-19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered.","J Eur Acad Dermatol Venereol","Torres-Navarro, Ignacio","Abril-Perez, Carlos","Roca-Gines, Juncal","Sanchez-Arraez, Javier","Botella-Estrada, Rafael","32455478"],"abstract":["We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID-19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered."],"journal":"J Eur Acad Dermatol Venereol","authors":["Torres-Navarro, Ignacio","Abril-Perez, Carlos","Roca-Gines, Juncal","Sanchez-Arraez, Javier","Botella-Estrada, Rafael"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32455478","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jdv.16664","keywords":["acute generalized exanthematous pustulosis (agep)","covid-19","sars-cov-2","severe cutaneous adverse reactions (scars)"],"e_drugs":["cefditoren"],"topics":["Treatment"],"weight":1,"_version_":1667983494515523585,"score":9.490897,"similar":[{"pmid":32386448,"title":"Acute Generalized Exanthematous Pustulosis with Erythema Multiforme-Like lesions in a COVID-19 woman.","text":["Acute Generalized Exanthematous Pustulosis with Erythema Multiforme-Like lesions in a COVID-19 woman.","The antimalarials, Chloroquine and Hydroxychloroquine (HCQ), and the antivirals Lopinavir/Ritonavir have been recently recorded as having anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) effects.(1) In particular, regarding Italy, one of the countries most affected by the pandemic, the Italian Society of Infectious and Tropical disease (Lombardy section) has recommended the use of HCQ for treatment of coronavirus disease 2019 (COVID-19).","J Eur Acad Dermatol Venereol","Robustelli Test, E","Vezzoli, P","Carugno, A","Raponi, F","Gianatti, A","Rongioletti, F","Sena, P","32386448"],"abstract":["The antimalarials, Chloroquine and Hydroxychloroquine (HCQ), and the antivirals Lopinavir/Ritonavir have been recently recorded as having anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) effects.(1) In particular, regarding Italy, one of the countries most affected by the pandemic, the Italian Society of Infectious and Tropical disease (Lombardy section) has recommended the use of HCQ for treatment of coronavirus disease 2019 (COVID-19)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Robustelli Test, E","Vezzoli, P","Carugno, A","Raponi, F","Gianatti, A","Rongioletti, F","Sena, P"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32386448","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jdv.16613","keywords":["acute generalized exanthematous pustulosis (agep)","covid-19","drug reaction","hydroxychloroquine (hcq)","skin","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Case Report"],"weight":1,"_version_":1666340101965217792,"score":180.7827},{"pmid":32294262,"title":"Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies.","text":["Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies.","We have read with great interest the article: Cutaneous manifestations in COVID-19: a first perspective by Recalcati S.(1) This article is the first report of the cutaneous manifestations in Coronavirus Disease 2019 (COVID-19) patients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Lombardy, Italy.","J Eur Acad Dermatol Venereol","Fernandez-Nieto, D","Ortega-Quijano, D","Segurado-Miravalles, G","Pindado-Ortega, C","Prieto-Barrios, M","Jimenez-Cauhe, J","32294262"],"abstract":["We have read with great interest the article: Cutaneous manifestations in COVID-19: a first perspective by Recalcati S.(1) This article is the first report of the cutaneous manifestations in Coronavirus Disease 2019 (COVID-19) patients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Lombardy, Italy."],"journal":"J Eur Acad Dermatol Venereol","authors":["Fernandez-Nieto, D","Ortega-Quijano, D","Segurado-Miravalles, G","Pindado-Ortega, C","Prieto-Barrios, M","Jimenez-Cauhe, J"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294262","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16470","keywords":["covid-19","exanthem","rash","skin","virus"],"locations":["Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"weight":0,"_version_":1666138494328635393,"score":173.09163},{"pmid":32294271,"title":"COVID-19 and Cutaneous manifestations.","text":["COVID-19 and Cutaneous manifestations.","We found that the article on \"Cutaneous manifestations in COVID-19: a first perspective\" is very interesting [1]. Recalcati noted that 20.4 % of the patients have cutaneous problem and mentioned that this is the first report on this clinical aspect of COVID-19.","J Eur Acad Dermatol Venereol","Mungmungpuntipantip, Rujittika","Wiwanitkit, Viroj","32294271"],"abstract":["We found that the article on \"Cutaneous manifestations in COVID-19: a first perspective\" is very interesting [1]. Recalcati noted that 20.4 % of the patients have cutaneous problem and mentioned that this is the first report on this clinical aspect of COVID-19."],"journal":"J Eur Acad Dermatol Venereol","authors":["Mungmungpuntipantip, Rujittika","Wiwanitkit, Viroj"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294271","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16483","topics":["Diagnosis"],"weight":1,"_version_":1666138494417764352,"score":160.23244},{"pmid":32314436,"title":"Comment on \"Cutaneous manifestations in COVID-19: a first perspective \" by Recalcati S.","text":["Comment on \"Cutaneous manifestations in COVID-19: a first perspective \" by Recalcati S.","Since the coronavirus disease 2019 (COVID 19) outbreak was first reported in the Chinese city of Wuhan on December 31, 2019, it has stricken more than 1,000,000 persons worldwide, of whom over 50,000 have died (1). Having been infected by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), patients with COVID-19 mainly present with fever and respiratory symptoms (2). Isolated sudden onset anosmia has also frequently been reported (3). Less frequently, rhinorrhea, diarrhoea and dysgeusia may be associated. While only a few reports have evoked cutaneous manifestations (4), we read with interest an initial study on the topic entitled \"Cutaneous manifestations in COVID-19: a first perspective \" by Recalcati S. (5).","J Eur Acad Dermatol Venereol","Hedou, M","Carsuzaa, F","Chary, E","Hainaut, E","Cazenave-Roblot, F","Masson Regnault, M","32314436"],"abstract":["Since the coronavirus disease 2019 (COVID 19) outbreak was first reported in the Chinese city of Wuhan on December 31, 2019, it has stricken more than 1,000,000 persons worldwide, of whom over 50,000 have died (1). Having been infected by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), patients with COVID-19 mainly present with fever and respiratory symptoms (2). Isolated sudden onset anosmia has also frequently been reported (3). Less frequently, rhinorrhea, diarrhoea and dysgeusia may be associated. While only a few reports have evoked cutaneous manifestations (4), we read with interest an initial study on the topic entitled \"Cutaneous manifestations in COVID-19: a first perspective \" by Recalcati S. (5)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Hedou, M","Carsuzaa, F","Chary, E","Hainaut, E","Cazenave-Roblot, F","Masson Regnault, M"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314436","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16519","keywords":["covid-19 infections","cutaneous manifestations","skin"],"locations":["Chinese","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493420568576,"score":151.71582},{"pmid":32294264,"title":"Cutaneous manifestations in COVID-19: a new contribution.","text":["Cutaneous manifestations in COVID-19: a new contribution.","We have read with great interest Dr Recalcati's review about skin manifestations in COVID-19 as it is the first report on this subject(1) . In a recent review on clinical characteristics of coronavirus disease 2019 in China, rash was observed in 0,2% of cases(2) . However, from the trained eyes of a dermatologist, this percentage may be higher.","J Eur Acad Dermatol Venereol","Estebanez, Andrea","Perez-Santiago, Leticia","Silva, Esmeralda","Guillen-Climent, Santiago","Garcia-Vazquez, Alejandro","Ramon, M Dolores","32294264"],"abstract":["We have read with great interest Dr Recalcati's review about skin manifestations in COVID-19 as it is the first report on this subject(1) . In a recent review on clinical characteristics of coronavirus disease 2019 in China, rash was observed in 0,2% of cases(2) . However, from the trained eyes of a dermatologist, this percentage may be higher."],"journal":"J Eur Acad Dermatol Venereol","authors":["Estebanez, Andrea","Perez-Santiago, Leticia","Silva, Esmeralda","Guillen-Climent, Santiago","Garcia-Vazquez, Alejandro","Ramon, M Dolores"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294264","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16474","keywords":["covid-19","cutaneous","cutaneous manifestations","skin"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138494356946945,"score":132.0418}]}